Advanced search
Publication Cover
Expert Opinion on Pharmacotherapy Volume 6, 2005 - Issue 12
Submit an article Journal homepage
41
Views
0
CrossRef citations to date
0
Altmetric
Key Paper Evaluation

Is the cannabinoid CB1 receptor antagonist rimonabant advancing the treatment of obesity?

VAN GAAL LF, SCHEEN AJ, ZIEGLER O, RÖSSNER S for the RIO-EUROPE STUDY GROUP: Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study. Lancet (2005) 365:1389-1397.

Sheila A Doggrell Division of Health Practice, Auckland University of Technology – Akoranga Campus, Northcote, Auckland, New Zealand. [email protected]
Pages 2141-2144 | Published online: 03 Oct 2005

Bibliography

  • PETERS A. BARENDREGT JJ, WILLEKENS F et al.: Obesity in adulthood and its consequences for life expectancy: a life-table analysis. Ann. Intern. Med. (2003) 138:24–32.
  • DI MARZO V, MATIAS I: Endocannabinoid control of food intake and energy balance. Nat. Neurosci. (2005) 8:585–589.
  • RAVINET TRILLOU C, DELGORGE C, MENET C, ARNONE M, SOUBRIE P: CB1 cannabinoid receptor knockout in mice leads to leanness, resistance to diet-induced obesity and enhances leptin sensitivity. Int. j Obes. Relat. Metab. Disorder. (2004) 28:640–648.
  • RAVINET TRILLOU C, ARNONEM, DELGORGE C et al.: Anti-obesity effect of 5R141716, a CB1 receptor antagonist, in diet-induced obese mice. Am. J. Physiol Regul Integr. Comp. Physiol (2003) 284:R345–R353.
  • VAN GAAL LF, SCHEEN AJ, ZIEGLER 0, ROSSNER S FOR THE RIO-EUROPE STUDY GROUP: Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study. Lancet (2005) 365:1389–1397.
  • SJOSTROM L, RISSANEN A, ANDERSEN T et al.: Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. European Multicentre Orlistat Study Group. Lancet (1998) 352:167–172.
  • HUTTON B, FERGUSSION D: Changes in body weight and serum lipid profile in obese patients treated with orlistat in addition to a hypocaloric diet: a systematic review of randomized clinical trials. Am. J. Clin. Nutr. (2004) 80:1461–1468.
  • PORTER JA, RAEBEL MA, CONNER DA et al.: The long-term outcomes of sibutramine effectiveness on weight (LOSE Weight) study: evaluating the role of drug therapy within a weight management program in a group-model health maintenance organization. Am. J. Manag-. Care (2004) 10:369–374.
  • FILAPPATOS TD, KIORTSIS DN, LIBEROPOULOS EN, MIKHAILIDIS DP, ELISAF MA: A review of the metabolic effects of sibutramine. Curr. Med. Res. Opin. (2005) 21:457–468.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.